Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
"I hope they will deliver a better-than-feared quarter when it reports on Thursday, but hope should never be part of the equation," the "Mad Money" host said. "As much as I do like the company ... the sector is having a very rough time."
There's a lot to like about Corteva, one of three companies that emerged from the recent DowDuPont breakup, Cramer argues. A pure play on agriculture, the entity is the second largest business in the industry formed through a tie-up of DuPont crop protection, DuPont Pioneer and Dow AgroSciences. The company makes genetically modified seeds — including corn, soybean, cotton and sunflower — intended to produce higher crop yields, he highlighted.
Corteva and Bayer, the largest player in the agribusiness arena, combined make up about 60% of U.S. seed sales, Cramer noted. Since its early-June spin-off, Corteva has climbed nearly 10%.
"This stock, Corteva, it reports again on Thursday morning and while there's not a lot of enthusiasm about the quarter, management has been pretty bullish about the second half of the year," Cramer said. "As Corteva prepared for its spin off, they told us the first half would be real ugly, but the second half would make up for that, and more so."
However, there are some red flags on the field as the agriculture group has been hit by a number of curveballs this year. The ongoing trade war with China has been tough on American farmers and flooding across the Midwest this year has made it a challenge to produce crops.
Corteva expects full-year sales to be flat, following a rough first-quarter report, Cramer said. Facing pressure from tariffs and rough weather conditions, sales in North America tumbled 22%. Organic crop protection sales climbed 1% in the first three-month period of 2019 while organic seed sales depleted 10%, he added.
The company has cut $1.2 billion of costs and expects to cut $500 million over the next five years, which should lead to earnings growth. Still, the results won't show up until 2020, a time frame that many analysts have mapped out, Cramer said.
The stock sells for 20-times next year's earnings estimates, a number that is "pretty reasonable for a company that might be able to generate 16% long-term earnings growth," the host said.
"Assuming they can meet those estimates, that's not expensive, although it could be a lot cheaper," he said. "So if you want to buy Corteva ... I think you should wait. I'm betting you'll get a better entry point than you're getting" here.